This is a Washington news story, published by Ars Technica, that relates primarily to Mounjaro news.
For more Washington news, you can click here:
more Washington newsFor more Mounjaro news, you can click here:
more Mounjaro newsFor more drug discoveries news, you can click here:
more drug discoveries newsFor more news from Ars Technica, you can click here:
more news from Ars TechnicaOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
dubious white powder customers. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest drug vendor news, tirzepatide drugs news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
vendor Pivotal PeptidesArs Technica
•
61% Informative
A drug vendor in Washington state is accused of selling do-it-yourself kits to make illicit knockoff versions of the brand-name drugs.
A lawsuit was filed by pharmaceutical giant Eli Lilly , maker of tirzepatide-based Zepbound and Mounjaro .
The lawsuit is one of three filed this week against Pivotal Peptides .
VR Score
42
Informative language
33
Neutral language
3
Article tone
semi-formal
Language
English
Language complexity
66
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
1
Source diversity
1
Affiliate links
no affiliate links